This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Delcath Systems’s 8K filing here.
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
See Also
- Five stocks we like better than Delcath Systems
- How to Invest in Biotech Stocks
- Micron: Why Now Is the Time to Be Brave
- What Are Dividend Achievers? An Introduction
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Reasons Costco Stock Will Have More Room to Run in 2025
